CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • MYOV Dashboard
  • Financials
  • Filings
  • Transcripts
  • ETFs
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Myovant Sciences (MYOV)

Company Profile
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Myovant Sciences has one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Its lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. Myovant Sciences is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is its majority shareholder.
Myovant Sciences logo

Company profile

Ticker
MYOV
Exchange
NYSE
Website
myovant.com
CEO
Lynn Seely
Employees
Incorporated
California
Location
United Kingdom
Fiscal year end
Mar 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...
SEC CIK
0001679082
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
Myovant Sciences, Inc. • Myovant Holdings Ltd. • Myovant Sciences GmbH • Myovant Sciences Ireland Limited • Myovant Treasury, Inc. • Myovant Treasury Holdings, Inc. ...

MYOV stock data

Latest filings (excl ownership)
View all
10-Q
2023 Q3
Quarterly report
26 Jan 23
8-K
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
26 Jan 23
SC 13E3/A
Going private transaction (amended)
23 Jan 23
DEFM14A
Proxy related to merger
23 Jan 23
SC 13E3/A
Going private transaction (amended)
6 Jan 23
PRER14A
Preliminary revised proxy
6 Jan 23
SC 13E3
Going private transaction
8 Dec 22
PREM14A
Preliminary proxy related to merger
8 Dec 22
10-Q
2022 Q2
Quarterly report
26 Oct 22
8-K
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022
26 Oct 22
Transcripts
View all
MYOV
Earnings call transcript
2022 Q1
28 Jul 22
MYOV
Earnings call transcript
2021 Q4
10 May 22
MYOV
Earnings call transcript
2021 Q3
26 Jan 22
MYOV
Earnings call transcript
2021 Q2
26 Oct 21
MYOV
Earnings call transcript
2021 Q1
28 Jul 21
MYOV
Earnings call transcript
2020 Q4
11 May 21
MYOV
Earnings call transcript
2020 Q3
11 Feb 21
MYOV
Earnings call transcript
2020 Q2
12 Nov 20
Latest ownership filings
View all
4
Matthew Lang
20 Jan 23
4
Lauren Merendino
20 Jan 23
4
David C Marek
20 Jan 23
4
Ferreira Juan Camilo Arjona
20 Jan 23
4
Ferreira Juan Camilo Arjona
5 Jan 23
4
Matthew Lang
5 Jan 23
4
Uneek Mehra
20 Dec 22
4
Terrie Curran
28 Oct 22
4
MARK GUINAN
28 Oct 22
4
Adele M. Gulfo
28 Oct 22

Financial summary

Financial statements Chart MYOV financial data
Quarter (USD) Dec 22 Sep 22 Jun 22 Mar 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Mar 22 Mar 21 Mar 20 Mar 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 256.76 mm 256.76 mm 256.76 mm 256.76 mm 256.76 mm 256.76 mm
Cash burn (monthly) 32.02 mm 17.59 mm 18.81 mm 13.52 mm 34.30 mm 22.49 mm
Cash used (since last report) 33.56 mm 18.43 mm 19.71 mm 14.17 mm 35.94 mm 23.57 mm
Cash remaining 223.20 mm 238.32 mm 237.05 mm 242.58 mm 220.81 mm 233.19 mm
Runway (months of cash) 7.0 13.5 12.6 17.9 6.4 10.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

MYOV institutional ownership history Ownership history
84.6% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 98 92 +6.5%
Opened positions 30 15 +100.0%
Closed positions 24 13 +84.6%
Increased positions 26 29 -10.3%
Reduced positions 23 28 -17.9%
13F shares Current Prev Q Change
Total value 1.46 bn 1.20 bn +22.2%
Total shares 82.29 mm 85.53 mm -3.8%
Total puts 601.60 k 539.70 k +11.5%
Total calls 353.70 k 553.70 k -36.1%
Total put/call ratio 1.7 1.0 +74.5%
Largest owners Shares Value Change
Sumitomo Chemical 50.04 mm $898.74 mm 0.0%
BBBOF BB Biotech 6.12 mm $95.32 mm 0.0%
BLVGF Bellevue 5.91 mm $106.19 mm -0.1%
Wellington Management 5.47 mm $98.16 mm -14.8%
JHG Janus Henderson 3.95 mm $71.01 mm -27.4%
Polar Capital 1.95 mm $34.98 mm NEW
BLK Blackrock 1.19 mm $21.31 mm +7.7%
Citadel Advisors 970.11 k $17.42 mm +0.1%
Vanguard 821.84 k $14.76 mm -4.3%
GS Goldman Sachs 491.16 k $8.82 mm +17.4%
Largest transactions Shares Bought/sold Change
STT State Street 0.00 -2.23 mm EXIT
Polar Capital 1.95 mm +1.95 mm NEW
JHG Janus Henderson 3.95 mm -1.50 mm -27.4%
Wellington Management 5.47 mm -951.11 k -14.8%
Marshall Wace 36.08 k -597.22 k -94.3%
Balyasny Asset Management 0.00 -417.50 k EXIT
Rhenman & Partners Asset Management AB 0.00 -310.00 k EXIT
Millennium Management 13.57 k -251.82 k -94.9%
IVZ Invesco 202.08 k +202.08 k NEW
Voloridge Investment Management 129.21 k +129.21 k NEW
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

MYOV insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
18 Jan 23 Arjona Ferreira Juan Camilo Common Shares Sell Dispose S No No 26.89 1,109 29.82 k 246,684
18 Jan 23 Marek David C Common Shares Sell Dispose S No No 26.89 8,037 216.11 k 417,599
18 Jan 23 Lauren Merendino Common Shares Sell Dispose S No No 26.89 2,008 54.00 k 169,538
18 Jan 23 Lang Matthew Common Shares Sell Dispose S No No 26.89 1,272 34.20 k 354,303
4 Jan 23 Lang Matthew Common Shares Sell Dispose S No No 26.9 2,779 74.76 k 355,575
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
Myovant Sciences Q3 Sales $100.20M Miss $102.36M Estimate
26 Jan 23
Myovant Sciences (NYSE:MYOV) reported quarterly sales of $100.20 million which missed the analyst consensus estimate of $102.36 million by 2.11 percent. This is a 7.17K percent increase over sales of $1.38 million the

Press releases

From Benzinga Pro
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
26 Jan 23
Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, LBAI, FCRD, MYOV
26 Jan 23
NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
25 Jan 23
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Myovant Sciences (NYSE:MYOV) to Sumitomo Pharma Co., Ltd.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBAI, IMRA, MYOV, IAA
12 Jan 23
MYOVANT SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
11 Jan 23
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn